



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 11 Apr 2016 (#11)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa Coetsee [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

## Important notices

- Request for Proposals (RFP): Nonhuman Primate Core Cellular Immunology Laboratory for Aids Vaccine Research And Development, NIAID-DAIDS-NIHAI2016060 ([NOT-AI-16-049](#)) National Institute of Allergy and Infectious Diseases
- Update to NIAMS Policy Regarding Submission of Clinical Trials Applications ([NOT-AR-16-015](#)) National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Revised Notice of Pre-application Teleconference for RFA-CA-16-009 "Early Detection Research Network: Biomarker Developmental Laboratories (U01)" ([NOT-CA-16-032](#)) National Cancer Institute
- NCI Announces Interest in Administrative Supplements to Generate Cancer Models to Advance Cancer Health Disparity Research ([NOT-CA-16-033](#)) National Cancer Institute
- Notice of Pre-application Webinar for PAR-16-105 "Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (U01)" ([NOT-CA-16-034](#)) National Cancer Institute
- Notice of Change to the Specific Areas of Research Interest for PA-15-082 "Drug Abuse Prevention Intervention Research (R01)" ([NOT-DA-16-021](#)) National Institute on Drug Abuse
- Request for Information: The Need for and Support of Research Resources for the Biomedical Research Community ([NOT-GM-16-103](#)) National Institute of General Medical Sciences
- AHRQ Announces Interest in Innovative Research in Primary Care ([NOT-HS-16-011](#)) Agency for Healthcare Research and Quality

### 1. Identification of Small Molecules for Sustained-Release Anti-HIV Products

**Letter of Intent due date:** July 1, 2016

**Hyperlink:** ([RFA-AI-16-024](#))

**Type:** R01

**Application Due Date:** August 3, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

**Purpose:** The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from single institutions, or consortia of institutions, to identify existing anti-HIV molecules, or discover new highly potent and selective anti-HIV small molecules, with the potential for development as sustained release products (SRP) with a dosing interval from once a week to once every three months or longer.

**Budget:** NIAID intends to commit \$2.0 million in FY 2017 to fund 2-4 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 2. Animal-Assisted Interventions for Special Populations

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** ([RFA-HD-17-015](#))  
([RFA-HD-17-014](#))

**Type:** R21  
R03

**Application Due Date:** July 29, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

**Purpose:** This FOA invites grant applications for research to examine the safety and efficacy of the inclusion of animals in therapy and rehabilitation for children and individuals with disabilities, neurological conditions, behavioral, emotional and mental health issues and related health outcomes, as well as the adaptation of healthy behaviors and the enhancement of learning in special need and at-risk populations.

**Budget:** NICHD intends to commit \$1,000,000 between this FOA and the companion FOA, RFA-HD-17-015 (R21), in fiscal year 2017 to fund 5-7 awards. **R21-**The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **R03-** No more than \$50,000 in direct costs may be requested in any single year. The total project period may not exceed 2 years.

## 3. Novel Strategies for Targeting HIV-CNS Reservoirs without Reactivation

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** ([RFA-MH-17-101](#))  
([RFA-MH-17-100](#))

**Type:** R01  
R21

**Application Due Date:** September 9, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

**Purpose:** This funding opportunity announcement invites research grant applications focused on: identifying HIV-1-infected cells in the central nervous system (CNS) compartment that are latently infected; developing strategies for targeting these latently infected cells; and aiming to achieve viral silencing leading to inhibition of viral production, without the need for pro-viral reactivation.

**Budget:** NIMH intends to commit an estimate of \$2,000,000 in FY 2017 to fund 4-5 awards in response to the R01 & R21 FOA. Future year amounts will depend on annual appropriations. NINDS intends to commit approximately \$1,500,000 in FY 2017 to fund 3-4 awards and NIDA will commit approximately \$1,500,000 in FY 2017 to fund 2-4 awards. **R01-** Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period for an application submitted in response to this FOA may not exceed five years. **R21 -**The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

## 4. Obesity Policy Evaluation Research

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** ([PA-16-165](#))

**Type:** R01

**Application Due Date:** [Standard dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

**Purpose:** This FOA encourages applications that propose to evaluate policies or large scale programs that are expected to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes have the potential to prevent or reduce rates of obesity.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 5. Diet and Physical Activity Assessment Methodology

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** ([PA-16-167](#))

**Type:** R01

**Application Due Date:** [Standard dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

**Purpose:** This FOA encourages innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted under this FOA are encouraged to include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modelling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed five years.

## 6. Understanding Factors in Infancy and Early Childhood (Birth to 24 months) That Influence Obesity Development

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** ([PA-16-169](#))

**Type:** R01

**Application Due Date:** [Standard dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

**Purpose:** This FOA invites applications from institutions/organizations which propose to characterize or identify factors in early childhood (birth-24 months) that may increase or mitigate risk for obesity and/or excessive weight gain and/or to fill methodological research gaps relevant to the understanding of risk for development of obesity in children. Studies should propose research in children from birth to 24 months, although

any proposed follow-up assessments, if applicable, may continue past this period. Studies may also assess factors relevant to families and/or caregivers of children from birth to 24 months. Applications should seek to fill unique research needs and involve expertise across disciplines as appropriate for the proposed research question.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed five years.

#### 7. Exploratory Grants in Cancer Epidemiology and Genomics Research

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(PA-16-175\)](#)

**Type:** R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

**Purpose:** This FOA invites applications for research on cancer epidemiology, genomics, and risk assessment. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance cancer research, such as improving epidemiologic study data collection; validating measurement of exposures in body fluids and tissues; applying epigenetic or metabolomic approaches to cancer epidemiology research; developing and applying novel strategies for discovery of risk variants for rare cancers; understanding the population genetic architecture of cancer in understudied populations; or validating methods to extract, collect, and synthesize clinical data via electronic medical records for use in observational studies of cancer patients and survivors. This FOA will utilize the exploratory/developmental research grant (R21) mechanism to foster cancer etiology and epidemiology research. While these studies may involve considerable risk, they may also lead to a breakthrough in a particular area, and to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (epidemiologic, biomedical, behavioral, or clinical).

**Budget:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in a single year. The maximum project period is 2 years.

#### 8. Pilot and Feasibility Studies Evaluating the Role of RNA Modifications (the 'epitranscriptome') in Cancer Biology

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(PA-16-177\)](#)

**Type:** R21

**Application Due Date:** [Standard dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

**Purpose:** This FOA encourages basic research into the role of RNA chemical modifications and their corresponding writers, readers and erasers in the initiation and progression of cancer. Chemical modifications of RNA bases have been reported to regulate the fate and function of both coding and noncoding RNAs and are emerging as a critical element of post-transcriptional gene regulation. This FOA will utilize the Exploratory/Developmental (R21) mechanism which supports investigation of novel scientific ideas or new model systems, tools or technologies that have the potential for significant impact on biomedical or biobehavioral research.

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 in direct costs can be requested in a single year.

#### 9. National Eye Institute Research Grant for Vision Related Secondary Data Analysis

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-16-168\)](#)

**Type:** R21

**Application Due Date:** [Standard dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

**Purpose:** This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis from vision related clinical trials, epidemiologic and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

#### 10. Noise-Induced Cochlear Synaptopathy: Basic Studies Informing Potential Therapies

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-16-170\)](#)

**Type:** R01

**Application Due Date:** November 3, 2016 and July 3, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

**Purpose:** This FOA invites research applications that will further our understanding of the cellular and subcellular basis of noise-induced cochlear synaptopathy. Such studies will increase our basic understanding of noise-induced cochlear synaptopathy as well as inform potential therapies.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. It is anticipated that projects supported by this FOA will require direct costs of less than \$500,000 per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 11. Innovation for HIV Vaccine Discovery

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-16-171\)](#)

**Type:** R01

**Application Due Date:** August 1, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

**Purpose:** The purpose of this FOA is to invite applications proposing innovative, high risk, high impact research to identify novel HIV vaccine concepts and targets. A further focus is to answer important scientific questions that will aid in the design and development of an effective immunogen that may provide long-term safe protection from either acquisition of, or ongoing infection by HIV. Thus, this FOA aims to support early discovery research by supporting the testing of novel hypotheses and approaches, and the potential for continued funding that is dependent upon achieving applicant-proposed and pre-award negotiated "Go/No-Go criterion/criteria" by the year-2 progress report.

**Budget:** Application budgets are limited to \$350,000 per year in direct costs. Applicants may request up to an additional \$150,000 in direct costs per year in any year when research in nonhuman primate or humanized mice models is proposed and justified. Applicants should submit a 4 year R01 application, and are required to identify Go/ No-Go decision criterion/criteria to be achieved as deliverables for the Year 2 progress report. Achievement of the stated goal(s) (Go) will enable continuation of the R01 for up to 4 years, while failure to achieve the stated goal(s) (No-Go) will result in negotiation of a reduced budget for Year 3 and award close out.

### 12. Research Partnerships for Scaling Up Mental Health Interventions in Low-and Middle-Income

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-16-174\)](#)

**Type:** U01

**Application Due Date:** July 15, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

**Purpose:** This FOA seeks applications to address implementation questions facing World Bank designated low- and middle-income countries (LMICs) in their efforts to scale up sustainable, evidence-based mental health interventions and thereby eliminate the mental health care treatment gap for children, women, and men. The mental health treatment gap refers to the proportion of persons who need but do not receive care. Each awarded project is to conduct implementation research and research capacity-building activities in LMICs in any one of the following geographical regions: East Asia and the Pacific; Europe and Central Asia; Latin America and the Caribbean; Middle East and North Africa; South Asia; Sub-Saharan Africa. As a group, awardees will constitute a network for mental health implementation research in LMICs with capabilities for answering research questions about going to scale with mental health interventions, sustaining high-quality mental health care in resource-limited settings, and fostering evidence-based mental health policy and program development on an ongoing basis. This program is not intended to support research that can be conducted primarily in and/or by United States or other high income country institutions.

**Budget:** Application budgets are limited to \$500,000 direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is five years.

### 13. National Cancer Institute Clinical and Translational Exploratory/Developmental Studies

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-16-176\)](#)

**Type:** R21

**Application Due Date:** July 19, 2016; November 22, 2016; March 22, 2017; July 19, 2017; November 22, 2017; March 22, 2018; July 19, 2018; November 22, 2018; March 22, 2018. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

**Purpose:** This FOA supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk, but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years.

**D71 - International Research Training Planning Grant:** To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

**D43 - International Research Training Grants:** To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

**DP1 – NIH Director’s Pioneer Award (NDPA):** To support individuals who have the potential to make extraordinary contributions to medical research. The NIH Director’s Pioneer Award is not renewable.

**DP3 – Institutional Training and Director Program Projects -Type 1 Diabetes Targeted Research Award:** To support research tackling major challenges in type 1 diabetes and promoting new approaches to these challenges by scientific teams.

**P20 – Research Program Projects and Centers -Exploratory Grant:** To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.

**R01 – NIH Research Project Grant Program:** most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

**R21 – NIH Exploratory/Developmental Research Grant:** encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

**R03 – NIH Small Grant Program:** limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

**R21/R33 - Phased Innovation:** The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

**R25 – NIH Education Projects:** used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

**R34 - Clinical Trial Planning Grant Program:** To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

**U01 – NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**U24 – Resource-Related Research Projects – Cooperative Agreements:** To support research projects contributing to improvement of the capability of resources to serve biomedical research.

**U01 – NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**UH2/UH3 – NIH Phase Innovation Awards Cooperative Agreement:** To support the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.) The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

**U2R – International Research Training Cooperative Agreements:** Cooperative agreement mechanism for D43 to support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

**U19 - Research Program-Cooperative Agreements:** supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

**Glossary of selected acronyms:**

<b>FOA</b>	Funding Opportunity Announcement
<b>PA</b>	Program Announcements ( <i>click on “PA” to search for further funding opportunities</i> )
<b>RFA</b>	Request for Applications ( <i>click on “RFA” to search for further funding opportunities</i> )

Complete [Glossary and acronym list of NIH Terms](#)